According to the website information of the State Food and Drug Administration (CFDA), the subsidiary of Sinopharm Holding Co., Ltd. is in the process of researching and manufacturing six types of generic drugs, capecitabine tablets. As of today, nearly 20 domestic production companies have joined together to declare the anti-cancer drugs and compete for the first big game in China.

Capecitabine is the first oral fluoropyrimidine carbamate antitumor drug that has been marketed and is a novel targeted drug for the treatment of breast cancer and colorectal cancer. The original manufacturer of the drug was Swiss Roche Pharmaceutical Co., Ltd. In 1998, it was marketed under the trade name xeloda in the United States, Canada, and Sweden. In March 2001, it was officially listed in China. Due to the convenience and safety of oral medications, they are highly favored by patients and bring huge profits to pharmaceutical companies. In 2007, global sales of capecitabine amounted to US$1.02 billion and in 2008, US$1.142 billion.

Heavy drugs are naturally favored by domestic pharmaceutical companies, and capecitabine is no exception. The patent period for the drug in China will expire on December 17, 2013. The rush of imitation has started since 2011. Hengrui Pharmaceutical and Qilu Pharmaceutical are the first phalanx of domestic first imitation companies. On-site inspections have been completed, and other patents can be approved upon expiry. This is the first line of attack for the first imitation; more than 10 drug companies such as Fuan Pharmaceutical and Tasly Not to be outdone, followed by the "in review" stage.

The domestic market for capecitabine is currently dominated by Roche and its joint venture Shanghai Roche, which accounted for 3.59% of the market for the entire anti-cancer drug market in China in 2011, ranking first among all anti-metabolic cancer drugs. Bit. With the advent of the patent period, a large area of ​​generic drugs was approved, and capecitabine was used as a medical insurance drug, and price cuts became an inevitable trend. Last year, the National Development and Reform Commission has adjusted the maximum retail price limit for some antitumor drugs. Some prices have fallen by nearly 40%. As a foreign company's patented drug, capecitabine has a lower decline.